Abstract | BACKGROUND: METHOD: Electronic databases were searched and calculated the weighted mean difference (WMD) with 95% confidence interval (CI) to assess the expression difference of NTx between BM+ and BM- lung cancer patients. Moreover, we conducted a sensitivity and specificity test and drew a summary receiver operating characteristic curve (SROC) to assess the diagnostic value of NTx in discerning bone metastasis. RESULTS: A total of eleven studies with 1108 individuals were included in this analysis. The results showed an increased NTx was correlated with the incidence of lung cancer (P < 0.001). The overall sensitivity and specificity of serum NTx (sNTx) for discerning bone metastasis was 0.74 (95% CI = 0.67 to 0.79) and 0.85 (95% CI = 0.80 to 0.89), respectively. As for urine NTx (uNTx) the pooled sensitivity and specificity was 0.77(95% CI = 0.67 to 0.86) and 0.81(95% CI = 0.76 to 0.86). The area under the SROC curve was 0.8889(SE = 0.0255) and 0.8655(SE = 0.0254) for sNTx and uNTx respectively. CONCLUSIONS: The elevation of NTx in lung cancer was positively related with the development and progression of bone metastasis. A higher specificity over sensitivity of NTx suggested that it is a more accurate biomarker to distinguish patients without bone metastasis. Regarding SROC curve, sNTx may be a better choice.
|
Authors | Boxuan Liu, Yun Zhao, Jingyan Yuan, Lizhong Zeng, Ruiying Sun, Xia Meng, Shuanying Yang |
Journal | PloS one
(PLoS One)
Vol. 12
Issue 11
Pg. e0187860
( 2017)
ISSN: 1932-6203 [Electronic] United States |
PMID | 29182642
(Publication Type: Journal Article, Meta-Analysis)
|
Chemical References |
- Biomarkers, Tumor
- Collagen Type I
- Peptides
- collagen type I trimeric cross-linked peptide
|
Topics |
- Biomarkers, Tumor
(blood)
- Bone Neoplasms
(diagnosis, secondary)
- Collagen Type I
(blood)
- Humans
- Lung Neoplasms
(pathology)
- Peptides
(blood)
- Sensitivity and Specificity
|